NEW YORK, Nov. 23 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) opened trading today on Safety First Trust Series 2007-4 Principal-Protected Trust Certificates Linked to a Global...
Akorn, Inc. (AMEX: AKN) today announced that it has signed an Exclusive Supply Agreement with PrimaPharm, Inc., a privately-held pharmaceutical company located in San Diego...
Akorn, Inc. (AMEX:AKN) today announced that its common stock listing application for the Nasdaq Global Market (Nasdaq) has been approved. Akorn expects to begin trading on the...
Akorn, Inc. (AMEX: AKN) today announced the positive results of a Phase III pivotal trial for Akten?. The clinical trial was a randomized, placebo controlled, multi-centered...
Akorn, Inc. (AMEX: AKN) today announced that it has signed a Definitive Agreement with Azad Pharma, a privately-held pharmaceutical company located in Toffen, Switzerland, to...
Akorn, Inc. (AMEX: AKN) and Strides Arcolab Limited (NSE: STAR, BSE: 532531) today announced that both Companies have agreed to fund, develop, and commercialize an additional 10...
Akorn, Inc. (AMEX:AKN) and Serum Institute of India, Ltd. today announced that they have entered into a Definitive Development and Exclusive Distribution Agreement for Rabies...
Akorn, Inc. (AMEX: AKN) today announced that it has added two injectable drug products to its API Supply and Margin Sharing Agreement with Natco Pharma Limited (NSE:...
Akorn, Inc. (AMEX:AKN) today reported net sales of $14.5 million for the third quarter 2006, an increase of 32% vs. third quarter 2005 net sales of $11.0 million. Gross profit...
Akorn, Inc. (AMEX:AKN) announced today that its third quarter 2006 earnings release has been scheduled for Monday, October 30, 2006, at 4:00 p.m. (Eastern Time). The Company...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約